Oxana Denisova receives 30 000 grant from Aamu foundation
Oxana Denisova receives 30 000 grant from Aamu foundation for her research on ‘PP2A in medulloblastoma therapy resistance: novel opportunities for targeted therapeutics.’
– My current research interest belongs to a field of brain cancer resistance and anticancer therapy development, particularly I focus on a role of protein phosphatase 2A (PP2A) and its inhibitor proteins in glioblastoma and pediatric medulloblastoma. I recently demonstrated that combination of PP2A reactivation and multi-kinase inhibition results in profound synergistic cell killing of adult glioblastoma and medulloblastoma cells, Oxana tells.
Recent Posts
- Meet our SAB over lunch!Turku Bioscience and BioCity Turku Scientific Advisory Board (SAB) is visiting Turku next week, and Read moreSeptember 16, 2026
- Dissertation Defence: Eleftheria MaranouMSc Eleftheria Maranou, from affiliated MIORG group, succesfully defended the dissertation in Immunology titled “The Achilles’ heel of Read moreSeptember 1, 2026
- Researchers discover molecular mechanism that helps aggressive colorectal cancer to spreadResearchers from the University of Turku in Finland, Turku Bioscience Centre and Gustave Roussy Institute Read moreAugust 25, 2026
- The Novo Nordisk Foundation has awarded funding of approximately one million euros to a research project led by Professor Jukka WestermarckThe Novo Nordisk Foundation has awarded funding of approximately one million euros to a research Read moreAugust 21, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026